<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461771</url>
  </required_header>
  <id_info>
    <org_study_id>POT-CP043014</org_study_id>
    <nct_id>NCT02461771</nct_id>
  </id_info>
  <brief_title>Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD</brief_title>
  <acronym>ASAP II</acronym>
  <official_title>Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to provide initial safety, tolerability and pharmacokinetics&#xD;
      information of intravitreal administration of pegcetacoplan in order to support further&#xD;
      development into larger Phase II studies for treatment of patients with AMD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2015</start_date>
  <completion_date type="Actual">March 8, 2016</completion_date>
  <primary_completion_date type="Actual">March 8, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Day 1 to Day 15</time_frame>
    <description>The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure ≥30 millimeters (mm) of mercury, and/or sustained loss of visual acuity ≥15 letters not attributable to the injection procedure or progression of disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])</measure>
    <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
    <description>The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Dose Normalized AUC(0-t)</measure>
    <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
    <description>The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
    <description>The median Cmax is presented for each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Dose Normalized Cmax</measure>
    <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
    <description>The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time to the Maximum Measured Serum Concentration (Tmax)</measure>
    <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
    <description>The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Visual Acuity for the Study Eye</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Macular Cube Volume in the Study Eye</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>Macular cube volume was determined using SD-OCT.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Pegcetacoplan Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg of pegcetacoplan 100 μL IVT injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegcetacoplan Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg of pegcetacoplan 100 μL IVT injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegcetacoplan Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg of pegcetacoplan 100 μL IVT injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegcetacoplan</intervention_name>
    <description>On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.</description>
    <arm_group_label>Pegcetacoplan Cohort 1</arm_group_label>
    <arm_group_label>Pegcetacoplan Cohort 2</arm_group_label>
    <arm_group_label>Pegcetacoplan Cohort 3</arm_group_label>
    <other_name>APL-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female&#xD;
&#xD;
          2. Age ≥ 50 years&#xD;
&#xD;
          3. The presence of an active choroidal neovascular lesion secondary to AMD&#xD;
&#xD;
          4. On treatment with anti-VEGF therapy (Lucentis®, Eylea® or Avastin®)&#xD;
&#xD;
          5. Must have received at least 3 anti-VEGF treatments over the 26-week period prior to&#xD;
             screening (Screening Visit)&#xD;
&#xD;
          6. Evidence that the macular fluid has responded to anti-VEGF in the past based on OCT in&#xD;
             the opinion of PI&#xD;
&#xD;
          7. At screening, evidence of subretinal fluid and retinal cystic changes&#xD;
&#xD;
          8. Must have received anti-VEGF treatment within 10 days prior to pegcetacoplan treatment&#xD;
             (anti-VEGF can be administered on the same day of the screening visit after the&#xD;
             screening procedures have been completed)&#xD;
&#xD;
          9. OCTs of sufficient quality to allow for the assessment of the central macular fluid&#xD;
             can be obtained&#xD;
&#xD;
         10. Female subjects must be:&#xD;
&#xD;
               -  Women of non-child-bearing potential (WONCBP), Or&#xD;
&#xD;
               -  Women of child-bearing potential (WOCBP) with a negative pregnancy test at&#xD;
                  screening and must agree to use protocol defined methods of contraception for the&#xD;
                  duration of the study&#xD;
&#xD;
         11. Males with female partners of child-bearing potential must agree to use protocol&#xD;
             defined methods of contraception and agree to refrain from donating sperm for the&#xD;
             duration of the study&#xD;
&#xD;
         12. Willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Choroidal neovascularization associated with other ocular diseases such as pathologic&#xD;
             myopia, ocular histoplasmosis or posterior uveitis, etc&#xD;
&#xD;
          2. Decreased vision due to retinal disease not attributable to choroidal&#xD;
             neovascularization, such as nonexudative forms of AMD, geographic atrophy, inherited&#xD;
             retinal dystrophy, uveitis or epiretinal membrane, a vitelliform-like lesion of the&#xD;
             outer retina (e.g., as in pattern dystrophies or basal laminar drusen), idiopathic&#xD;
             parafoveal telangiectasis, or central serous retinopathy&#xD;
&#xD;
          3. Additional ocular diseases that have irreversibly compromised or, during follow-up,&#xD;
             could likely compromise the VA of the study eye including amblyopia, anterior ischemic&#xD;
             optic neuropathy, clinically significant diabetic macular edema, severe non&#xD;
             proliferative diabetic retinopathy, or proliferative diabetic retinopathy&#xD;
&#xD;
          4. Decreased vision due to significant media opacity such as corneal disease or cataract,&#xD;
             or opacity precluding photography of the retina&#xD;
&#xD;
          5. Cataract surgery within three months of enrollment&#xD;
&#xD;
          6. Presence of any hemorrhage&#xD;
&#xD;
          7. History of treatment for CNV:&#xD;
&#xD;
               1. Previous PDT treatment within 30 days prior to enrollment in the study&#xD;
&#xD;
               2. Previous extrafoveal or juxtafoveal thermal laser photocoagulation within 30 days&#xD;
                  prior to enrollment in the study&#xD;
&#xD;
          8. Intraocular surgery (including lens replacement surgery) within 3 months prior to&#xD;
             randomization&#xD;
&#xD;
          9. Medical problems that make consistent follow-up over the treatment period unlikely&#xD;
             (e.g. stroke, severe MI, end stage malignancy), or in general a poor medical risk&#xD;
             because of other systemic diseases or active uncontrolled infections&#xD;
&#xD;
         10. Hypersensitivity to fluorescein&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Grossi, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Apellis Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>United States, California</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, New Hampshire</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australia, New South Wells</name>
      <address>
        <city>Parramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>Neovascular AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male and female subjects aged at least 50 years with the presence of an active choroidal neovascular lesion secondary to age-related macular degeneration were recruited to this Phase 1 open-label, single-dose escalation study at 4 study centers in the United States and Australia.</recruitment_details>
      <pre_assignment_details>Subjects had received at least 3 anti-vascular endothelial growth factor treatments over the 26 week period prior to screening, and were enrolled into 1 of 3 cohorts to receive pegcetacoplan (previously known as APL-2). If both eyes were eligible for the study, the subject and Principal Investigator chose the eye that served as the study eye.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>4 milligrams (mg) pegcetacoplan: Subjects received a single intravitreal (IVT) injection of pegcetacoplan (100 microliters [μL] of 40 mg per milliliter [mg/mL]) on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set included all subjects who received any amount of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="60" upper_limit="73"/>
                    <measurement group_id="B2" value="79" lower_limit="74" upper_limit="81"/>
                    <measurement group_id="B3" value="72" lower_limit="68" upper_limit="93"/>
                    <measurement group_id="B4" value="73" lower_limit="60" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity</title>
        <description>Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.</description>
        <time_frame>Day 1 to Day 113</time_frame>
        <population>The safety set included all subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity</title>
          <description>Safety was assessed throughout the study. A TEAE was defined as any AE that started on/after the IVT injection of pegcetacoplan.</description>
          <population>The safety set included all subjects who received any amount of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose Limiting Toxicities (DLTs)</title>
        <description>The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure ≥30 millimeters (mm) of mercury, and/or sustained loss of visual acuity ≥15 letters not attributable to the injection procedure or progression of disease.</description>
        <time_frame>Day 1 to Day 15</time_frame>
        <population>The safety set included all subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Limiting Toxicities (DLTs)</title>
          <description>The occurrence of any of the following AEs were considered DLTs: intraocular inflammation (vitritis or uveitis), endophthalmitis, sustained elevation of intraocular pressure ≥30 millimeters (mm) of mercury, and/or sustained loss of visual acuity ≥15 letters not attributable to the injection procedure or progression of disease.</description>
          <population>The safety set included all subjects who received any amount of study drug.</population>
          <units>Number of DLTs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])</title>
        <description>The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.</description>
        <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
        <population>The pharmacokinetic (PK) set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Area Under the Serum Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC[0-t])</title>
          <description>The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The median AUC(0-t) is presented for each cohort.</description>
          <population>The pharmacokinetic (PK) set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
          <units>micrograms*day/milliliter (μg*day/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.89" lower_limit="11.49" upper_limit="13.90"/>
                    <measurement group_id="O2" value="29.95" lower_limit="24.27" upper_limit="53.59"/>
                    <measurement group_id="O3" value="69.53" lower_limit="55.06" upper_limit="86.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Dose Normalized AUC(0-t)</title>
        <description>The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.</description>
        <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
        <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Dose Normalized AUC(0-t)</title>
          <description>The AUC(0-t) was measured using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing. The dose normalized AUC(0-t) was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized AUC(0-t) is presented for each cohort.</description>
          <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
          <units>(μg*day/mL)/respective mg dose</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" lower_limit="2.87" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.43" upper_limit="5.36"/>
                    <measurement group_id="O3" value="3.48" lower_limit="2.75" upper_limit="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Serum Concentration (Cmax)</title>
        <description>The median Cmax is presented for each cohort.</description>
        <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
        <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax)</title>
          <description>The median Cmax is presented for each cohort.</description>
          <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
          <units>μg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.383" lower_limit="0.317" upper_limit="0.387"/>
                    <measurement group_id="O2" value="0.764" lower_limit="0.596" upper_limit="1.610"/>
                    <measurement group_id="O3" value="2.140" lower_limit="1.440" upper_limit="3.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Dose Normalized Cmax</title>
        <description>The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.</description>
        <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
        <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Dose Normalized Cmax</title>
          <description>The dose normalized Cmax was calculated for each subject by dividing the parameter by the subject's respective dose in milligrams. The median dose normalized Cmax is presented for each cohort.</description>
          <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
          <units>(μg/mL)/respective mg dose</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" lower_limit="0.079" upper_limit="0.097"/>
                    <measurement group_id="O2" value="0.076" lower_limit="0.060" upper_limit="0.161"/>
                    <measurement group_id="O3" value="0.107" lower_limit="0.072" upper_limit="0.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time to the Maximum Measured Serum Concentration (Tmax)</title>
        <description>The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.</description>
        <time_frame>Predose (screening), postdose Day 3 to Day 113</time_frame>
        <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to the Maximum Measured Serum Concentration (Tmax)</title>
          <description>The median Tmax is presented for each cohort. If the maximum value occurred at more than 1 time point, Tmax was defined as the first time point with this value.</description>
          <population>The PK set included all subjects in the safety set who had at least one postdose PK sample drawn with a measurable serum concentration of the study drug (even if the concentration was &lt; lower limit of quantification).</population>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="8.9" upper_limit="14.9"/>
                    <measurement group_id="O2" value="7.9" lower_limit="7.0" upper_limit="14.9"/>
                    <measurement group_id="O3" value="15.0" lower_limit="6.9" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Visual Acuity for the Study Eye</title>
        <description>Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
        <time_frame>Day 1 to Day 113</time_frame>
        <population>The efficacy set included all subjects who received any amount of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Visual Acuity for the Study Eye</title>
          <description>Best Corrected Visual Acuity (BCVA) letter score was determined using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. The score ranges from 0 to 100 letters, lower number indicating reduced visual acuity; a positive value of change from baseline indicates visual acuity gain and a negative value indicates visual acuity loss.</description>
          <population>The efficacy set included all subjects who received any amount of the study drug.</population>
          <units>letters read correctly</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="-9" upper_limit="11"/>
                    <measurement group_id="O3" value="-1" lower_limit="-4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye</title>
        <description>Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).</description>
        <time_frame>Day 1 to Day 113</time_frame>
        <population>The safety set included all subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Central Retinal Thickness, Central Retinal Lesion Thickness and Central Subfield Thickness in the Study Eye</title>
          <description>Central retinal thickness, central retinal lesion thickness and central subfield thickness were determined using Spectral Domain Optical Coherence Tomography (SD-OCT).</description>
          <population>The safety set included all subjects who received any amount of study drug.</population>
          <units>micrometers</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Retinal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-106" lower_limit="-129" upper_limit="71.5"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-109" upper_limit="22.0"/>
                    <measurement group_id="O3" value="37.5" lower_limit="-9.5" upper_limit="170.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retinal lesion thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.5" lower_limit="-128" upper_limit="64.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="-104" upper_limit="31.5"/>
                    <measurement group_id="O3" value="19.0" lower_limit="-21.5" upper_limit="212.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Subfield Thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" lower_limit="-48.0" upper_limit="42.0"/>
                    <measurement group_id="O2" value="-12.0" lower_limit="-80.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="65.0" lower_limit="-11.0" upper_limit="138.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Macular Cube Volume in the Study Eye</title>
        <description>Macular cube volume was determined using SD-OCT.</description>
        <time_frame>Day 1 to Day 113</time_frame>
        <population>The safety set included all subjects who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Macular Cube Volume in the Study Eye</title>
          <description>Macular cube volume was determined using SD-OCT.</description>
          <population>The safety set included all subjects who received any amount of study drug.</population>
          <units>mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-2.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.3" lower_limit="-0.3" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs were collected from Day 1 up to the final study visit at Day 113 (approximately 16 weeks).</time_frame>
      <desc>The safety set included all subjects who received any amount of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>4 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 40 mg/mL) on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>10 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 100 mg/mL) on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>20 mg pegcetacoplan: Subjects received a single IVT injection of pegcetacoplan (100 μL of 200 mg/mL) on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Apellis Clinical Trial Information Line</name_or_title>
      <organization>Apellis Pharmaceuticals, Inc</organization>
      <phone>1-833-284-6361</phone>
      <email>clinicaltrials@apellis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

